Atria Investments Inc Has $274,000 Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Atria Investments Inc boosted its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 7.0% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 17,134 shares of the company’s stock after purchasing an additional 1,116 shares during the period. Atria Investments Inc’s holdings in Centessa Pharmaceuticals were worth $274,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of CNTA. First Light Asset Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after purchasing an additional 1,778,515 shares during the period. Perceptive Advisors LLC lifted its stake in Centessa Pharmaceuticals by 27.6% in the second quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock valued at $35,518,000 after buying an additional 850,000 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Centessa Pharmaceuticals by 16.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock worth $33,427,000 after buying an additional 418,615 shares in the last quarter. Driehaus Capital Management LLC grew its position in shares of Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after buying an additional 987,997 shares during the period. Finally, Farallon Capital Management LLC increased its stake in shares of Centessa Pharmaceuticals by 438.0% in the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after acquiring an additional 1,625,000 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 16,619 shares of the business’s stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total transaction of $260,752.11. Following the transaction, the insider now directly owns 206,750 shares in the company, valued at approximately $3,243,907.50. The trade was a 7.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Saurabh Saha sold 175,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total transaction of $2,891,000.00. Following the completion of the sale, the chief executive officer now directly owns 776,924 shares of the company’s stock, valued at $12,834,784.48. The trade was a 18.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 364,829 shares of company stock valued at $5,966,472. 11.59% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CNTA shares. Oppenheimer reissued an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. B. Riley began coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price for the company. Jefferies Financial Group boosted their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Guggenheim increased their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Finally, BMO Capital Markets boosted their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $17.04 on Friday. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -11.14 and a beta of 1.47. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a fifty-two week low of $5.58 and a fifty-two week high of $18.74. The firm’s 50-day simple moving average is $16.09 and its 200 day simple moving average is $12.38.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, research analysts anticipate that Centessa Pharmaceuticals plc will post -1.62 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.